Last reviewed · How we verify
Vernal keratoconjunctivitis
Approved treatments
- Intal · Pfizer
- Cromoglicate · LEO Pharma
- Alomide · Novartis
- Cromoglycate · Vishwajit Nimgaonkar, MD PhD
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Vernal keratoconjunctivitis patent landscape — cliff calendar, originator estates, attackable patents
- Vernal keratoconjunctivitis treatment landscape brief
- Vernal keratoconjunctivitis treatment updates RSS
Frequently asked questions about Vernal keratoconjunctivitis
What drugs treat Vernal keratoconjunctivitis?
Tracked treatments include Intal, Cromoglicate, Alomide, Cromoglycate.
What is the treatment for Vernal keratoconjunctivitis?
Standard treatment for Vernal keratoconjunctivitis includes Intal, Cromoglicate, Alomide, Cromoglycate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Vernal keratoconjunctivitis patent cliff · Vernal keratoconjunctivitis CI report
- Treatment: Intal · Pfizer
- Treatment: Cromoglicate · LEO Pharma
- Treatment: Alomide · Novartis
- Treatment: Cromoglycate · Vishwajit Nimgaonkar, MD PhD
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing